CFDE Data Portal | Search GAR1-DT

	Label	Description
	GAR1-DT Gene (Entity type)	ENSG00000272795 - GAR1 divergent transcript
	GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE216988 GSE216989 decitabine 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE212330 azacitidine 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE104022 1 V 0 TAMOXIFEN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE153871 cytarabine U2OS 0 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE151090 verteporfin 2 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 sulforaphane 2 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE57871 GLI1 PSMD13 knockdown HCT 116 Vorinostat 8 v 12 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE57871 vorinostat HCT 116 8 v 12 human up Gene Set (Entity type)	A Gene Set from LINCS

GAR1-DT

ENSG00000272795 - GAR1 divergent transcript

GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN

A Gene Set from LINCS

GSE216988 GSE216989 decitabine 0 v 1 human up

A Gene Set from LINCS

GSE212330 azacitidine 1 v 0 human dn

A Gene Set from LINCS

GSE104022 1 V 0 TAMOXIFEN MOUSE DN

A Gene Set from LINCS

GSE153871 cytarabine U2OS 0 v 3 human dn

A Gene Set from LINCS

GSE151090 verteporfin 2 v 4 human up

A Gene Set from LINCS

GSE48812 sulforaphane 2 v 5 human up

A Gene Set from LINCS

GSE57871 GLI1 PSMD13 knockdown HCT 116 Vorinostat 8 v 12 human up

A Gene Set from LINCS

GSE57871 vorinostat HCT 116 8 v 12 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.